Basilea has entered into an asset purchase agreement with the Glioblastoma Foundation, for Basilea’s oncology drug candidate lisavanbulin (BAL101553), which has been developed as a potential therapy for glioblastoma,...

View the Online Magazine

Launches

M3 EU launches M3 Production, a complete solution to transform pharmaceutical marketing

M3 EU is delighted to launch M3 Production, a specialist pharmaceutical production service designed to streamline marketing efforts, optimise resources and enhance the overall...

Beckman Coulter’s DxI 9000 Immunoassay Analyzer extends menu with new CE-marked hepatitis assays at ESCMID Global

Beckman Coulter Diagnostics, a leader in clinical diagnostics, announced today, ahead of the congress of the European Society of Clinical Microbiology and Infectious Diseases...

Getinge and CellRev launch pioneering adherent cell expansion platform

CellRev, in partnership with Getinge, has launched a breakthrough adherent cell expansion platform, Livit ACE. Designed to eliminate many of the limitations and inefficiencies associated...

Suppliers Guide

Check out our Suppliers Guide or contact our team and get your company listed

Subscribe

Keep up with what's happening in the industry and subscribe to our weekly newsletter

Events

Get your event seen by potential candidates on the world's leading industry site.

Supply Chain

Merck completes €180m investment at distribution center

Merck has opened its newly expanded Life Science distribution center in Schnelldorf, Germany. The investment of €180 million added 25,000 square meters to the...

WHO prequalifies new dengue vaccine

A new vaccine for dengue has received prequalification from the World Health Organization (WHO). TAK-003 is the second dengue vaccine to be prequalified by...

ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year

ACG, the world’s largest integrated supplier and service provider to the pharmaceutical industry, is delighted to announce that for the fourth consecutive year, it...

Emergent BioSolutions receives $75m contract option from BARDA to procure doses of anthrax vaccine

The Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response at the United States Department of Health and...

Approvals

European Commission grants Sobi Marketing Authorisation for ALTUVOCT for treatment of haemophilia A

The European Commission has granted Marketing Authorisation for Sobi's ALTUVOCT (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia...

European Commission approves Takeda’s FRUZAQLA in previously treated metastatic colorectal cancer

The European Commission (EC) has approved Takeda's FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC)...

Manufacturiung

Finance

Research & Development
Latest

Basilea enters into asset purchase agreement with Glioblastoma Foundation for oncology drug candidate

Basilea has entered into an asset purchase agreement with the Glioblastoma Foundation, for Basilea’s oncology drug candidate lisavanbulin (BAL101553), which has been developed as...

Ascidian Therapeutics collaborates with Roche for development of RNA exon editing therapeutics targeting neurological diseases

Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, has announced a research collaboration and licensing agreement with Roche for...

Belharra Therapeutics and Sanofi to advance discovery of novel small molecule therapeutics for immunological diseases

Belharra Therapeutics, a next-generation chemoproteomics company transforming small molecule drug discovery by illuminating binding pockets on elusive, high-value drug targets across the proteome, has...

Plurify and Cell and Gene Therapy Catapult to develop technology that improves purity of cell therapies

The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy...

AbbVie and FutureGen to develop next-generation therapy for inflammatory bowel disease

AbbVie and FutureGen have announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of inflammatory bowel disease (IBD)...

Appointments